title: Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
abstract: Drug-induced movement disorders have dramatically declined with the widespread use of second-generation antipsychotics, but remain important in clinical practice and for understanding antipsychotic pharmacology. The diagnosis and management of dystonia, parkinsonism, akathisia, catatonia, neuroleptic malignant syndrome, and tardive dyskinesia are reviewed in relation to the decreased liability of the second-generation antipsychotics contrasted with evidence from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Data from the CATIE trial imply that advantages of second-generation antipsychotics in significantly reducing extrapyramidal side effects compared with haloperidol may be diminished when compared with modest doses of lower-potency first-generation drugs.
authors.affiliation: Department of Psychiatry, Veterans Affairs Medical Center-116A, University & Woodland Avenues, Philadelphia, PA 19104, USA. stanley.caroff@va.gov
authors.forename: Stanley N
authors.initials: SN
authors.lastname: Caroff
authors.forename: Irene
authors.initials: I
authors.lastname: Hurford
authors.forename: Janice
authors.initials: J
authors.lastname: Lybrand
authors.forename: E Cabrina
authors.initials: EC
authors.lastname: Campbell
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D002986:Clinical Trials as Topic; D006801:Humans; D009069:Movement Disorders / Q000145:classification / Q000209:etiology*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents